| Methods | D: crossover C: unclear B: double WD: 7/35 J: 1‐2‐0 DU: ‐/2x6w (1w)/‐ | |
| Participants | N: 35/28 D: 6 migraine with, 29 without aura C: Ad Hoc F: 69% A: 25‐60 years DU: not reported S: unclear, Norway | |
| Interventions | P: 160 mg C1: Placebo C2: Atenolol 100 mg | |
| Outcomes | R: not reported F: 9.2 vs. 10.3 vs. 8.8 (headache days; sd not reported) AU: not reported HI: not reported AEs: more with propranolol Dropouts‐AEs: 1/35 vs. 0/35 vs. 0/35 V: (+) vs. C1, 0 vs. C2 | |
| Notes | Results reported insufficiently | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.